Intriguingly, a novel dual function ACLY inhibitor/AMPK activator has entered clinical trials for metabolic diseases [70]; such a compound could be attractive to test for efficacy in prostate cancer along with an AR antagonist. This evidence concerns the gene AR and prostate carcinoma.